TG Therapeutics (TGTX) News
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
63.34-1.54 (-2.37%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TGTX news summary
We found 50 recent headlines mentioning TG Therapeutics (TGTX): 2 in the past week and 50 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, TGTX is down 2.37% at $63.34. The most recent story, "TG Therapeutics: The Price Already Pays For Growth That Ocrevus Copies Can Cut Short", was published by Seeking Alpha on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest TG Therapeutics headlines
- TG Therapeutics: The Price Already Pays For Growth That Ocrevus Copies Can Cut ShortSeeking Alpha
- 3 Stocks Rallying After Strong Q3 Earnings and Raised GuidanceThe Q3 earnings season has delivered several big winners, with Hasbro (HAS), IDEXX Laboratories (IDXX), and TG Therapeutics (TGTX) all posting strong results that have helped drive relative strength…NasdaqHAS, IDXX, TGTX
- TG Therapeutics: 3 Key Takeaways for Long-Term InvestorsKey PointsTG Therapeutics raised full-year 2026 global revenue guidance to $1 billion.NasdaqTGTX, BRK.A
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and MadrigalTGTX, BCRX, INSM and MDGL are expanding commercial reach through rising therapy sales, broader patient access and potential new indications.NasdaqBCRX, INSM, TGTX, MDGL
- TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock UpTG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.NasdaqTGTX, HALO, COLL, AMRX
- How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, NovartisTG Therapeutics is Tuesday's IBD Stock Of The Day. Shares topped a buy zone despite a mixed Q3 report, but are in range of an alternate entry. The post How IBD Stock Of The Day TG Therapeutics Is…Investor's Business DailyTGTX, NVS
- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.NasdaqIBRX, HALO, TGTX, AMRX
- CRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioCorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.NasdaqCRMD, TGTX, HRTX, AMRX
- 4 Commercial-Stage Biotechs Poised for Sustained Revenue GrowthTGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.NasdaqBCRX, INSM, TGTX, MDGL
- TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call TranscriptSeeking Alpha
- What TG Therapeutics (TGTX) Said on Its Q3 Earnings CallThe Most Shorted Stocks in June: Hold, Short, or Squeeze?TG Therapeutics (NASDAQ:TGTX) raised its 2026 revenue outlook after third-quarter sales of its multiple sclerosis treatment BRIUMVI climbed…Nasdaq
- TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceTG Therapeutics, Inc. reported its financial results for the third quarter of 2026, with total global revenue of $259.9 million and BRIUMVI U.S. net product revenue of $232.6 million. Net income was…Nasdaq
- TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to SayThe headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…Nasdaq
- TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue EstimatesTG Therapeutics (TGTX) delivered earnings and revenue surprises of +25.00% and +5.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqTGTX, GOSS
- TG Therapeutics GAAP EPS of $0.35 misses by $0.01, revenue of $259.9M beats by $14.45MSeeking Alpha
- TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceNEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent…Business Wire
- Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in FocusNTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.NasdaqNTLA, REGN, TGTX, AMRX
- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownAGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.NasdaqAGEN, TGTX, AMRX, IBRX
- IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D CostsIovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.NasdaqIOVA, MRK, TGTX, AMRX
- TG Therapeutics Q3 2026 Earnings PreviewSeeking Alpha
- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthHarmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.NasdaqHRMY, TGTX, TAK, TARS
- ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock UpZoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.NasdaqZTS, TGTX, AMRX, IBRX
- Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/YVTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.NasdaqVTRS, TGTX, AMRX, IBRX
- Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue EstimatesLexicon (LXRX) delivered earnings and revenue surprises of +50.00% and +3.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqLXRX, TGTX
- Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?Agilent Technologies gears up for Q4 fiscal 2026 earnings, with revenues and EPS growth expected amid strength in chromatography, spectroscopy and consumables.NasdaqA, TGTX, CRBU, AARD
- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesOCGN's Q3 revenues beat estimates. Shares surge 17.4%. Advancing gene therapy programs target three BLA submissions by 2028.NasdaqOCGN, TGTX, TARS
- Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock UpTeva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.NasdaqTEVA, BMY, TGTX, TARS
- CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y RevenuesCorcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.NasdaqCORT, TGTX, TARS
- AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedAmneal tops Q3 estimates as strong Affordable Medicines and Specialty growth drives higher 2026 guidance and boosts its growth outlook.NasdaqAMRX, TGTX, IOVA, IBRX
- 4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesFour biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.NasdaqTGTX, RGNX, IMNM, PMN
- NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook RaisedNovo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.NasdaqNVO, TGTX, IOVA, IBRX
- NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewNeurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.NasdaqNBIX, TGTX, AMRX
- JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales ViewJazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.NasdaqJAZZ, TGTX, AMRX
- CRSP's Q3 Loss Wider Than Expected, Sales Beat EstimatesCRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.NasdaqCRSP, VRTX, TGTX, AMRX
- Zoetis Gears Up to Report Q3 Earnings: Here's What to ExpectZTS heads into Q3 earnings with international growth, livestock strength and demand for key companion animal products offsetting U.S. market challenges.NasdaqZTS, TGTX, IOVA, JSPR
- VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedVertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.NasdaqVRTX, TGTX, CRSP
- Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.NasdaqVTRS, TGTX, ACAD, IOVA
- ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?Eton's Q3 growth is likely to have been driven by rising sales of Increlex, Alkindi Sprinkle and other key products, alongside contributions from recent launches.NasdaqETON, TGTX, IOVA, AMRX
- TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business UpdateNEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the…Business Wire
- Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?TECH's Q1 earnings are on deck, with revenues and EPS growth expected as investors weigh segment performance and the pending $11.3 billion acquisition.NasdaqTECH, ACHC, TGTX, RVTY
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthGilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.NasdaqGILD, TGTX, IOVA, AMRX
- INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceInsmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.NasdaqINSM, TGTX, IOVA, AMRX
- Edwards' Q3 Earnings on the Horizon: What's in the Cards?EW heads into Q3 with TAVR momentum, expanding mitral and tricuspid therapies and surgical heart growth. Can it beat earnings estimates?NasdaqEW, ACHC, TGTX, RVTY
- INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedIncyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.NasdaqINCY, NVS, LLY, TGTX
- VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesViking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.NasdaqVKTX, TGTX, AMRX
- Amarin's Q3 Earnings Beat Estimates, Revenues Miss MarkAMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.NasdaqAMRN, TGTX, IOVA, AMRX
- GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive GrowthGRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.NasdaqACHC, TGTX, RVTY
- Noteworthy ETF Outflows: IJT, PTGX, VSAT, TGTXLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P Small-Cap 600 Growth ETF (Symbol: IJT) where we have…NasdaqIJT, PTGX, VSAT, TGTX
- BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesBausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.NasdaqBHC, TGTX, IOVA, AMRX